Microcap Alpha and Its Capacity Limits

Almost every famous academic anomaly — value, momentum, quality — looks strongest when you include microcap stocks, and weakens noticeably once you restrict the universe to large, liquid names. That's not a coincidence: microcaps are less researched, less arbitraged away, and thinly traded, so mispricings linger there longer than in a stock every analyst on the Street covers. A backtest built on an equal-weighted universe of the smallest 20% of listed names will routinely show double the Sharpe ratio of the same signal applied to the largest 20%.

The catch is capacity. A microcap might trade $200,000 of average daily volume; a fund trying to build a meaningful position without moving the price is capped at a small fraction of that per day, meaning a strategy that looks spectacular on paper might only support a few million dollars of capital before trading costs and market impact eat the edge alive. Large institutional managers routinely exclude the bottom decile of market cap from their investable universe for exactly this reason — the alpha is real, but it doesn't scale.

This is why "backtested Sharpe ratio" and "investable Sharpe ratio" can diverge so sharply: the first ignores capacity, the second is capped by how much capital the underlying liquidity can actually absorb without moving the price against you. A rough industry rule of thumb caps a single position at some small single-digit percentage of a stock's average daily volume, which for a genuine microcap can mean a strategy's entire viable capacity tops out in the low millions of dollars regardless of how good the underlying signal is.